STAT+: Invivyd's pursuit of a Covid vaccine alternative gets a lift, but an FDA hurdle may await

Small biotech company Invivyd is developing an injectable, low-dose monoclonal antibody intended to protect against Covid. According to the report, its pursuit of a Covid vaccine alternative has received a lift, but an FDA hurdle may await; no efficacy conclusions are stated in the item.

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.